Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep186 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Cardiorenal outcomes and T2DM control in new users of SGLT2 inhibitors in combination therapy

Ihintza Larrañaga , Vives Cristina Goena , Maria Magdalena Arteaga Ossa , Jose Francisco Egido Arroyo , Begoña Maíz Alcorta , Laura Mañas Alonso , Ovejero Laura Quintas , Rodrigo Ana Moreno , Nerea Andrés Imaz , Amaia Cristina Armentia Del Pozo , Abasolo Amaia Aspiazu , Villar Ruth Agirrezabalaga , Irene Larrañaga Gomez , Irizar Sara Diez , Suarez Teresa Arana , Dadebat Naroa Rico , Josu Pérez Yéboles

Introduction and objectivesSGT2i have changed the paradigm of T2DM management. Last guidelines insist on the importance of using newer glucose-lowering drugs with a demonstrated reduction in cardiovascular events (CVE). The aim of this study is twofold: to describe CVE, heart failure (HF) and renal function evolution; and to assess its efficacy in non-selected patients with T2DM initiating SGLT2iMaterial and methods<p class="ab...